Suchergebnisse - "Lenalidomide"

PubPharm (5.975)

51

Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma : an indirect treatment comparison

enthalten in: Leukemia & lymphoma | 2024

von Weisel, K. | Dimopoulos, M. | Beksac, M. | +7

52

Improved Side Effect Profile of Alternate-Day Dosing of Lenalidomide

enthalten in: Cureus | 2024

von Lawal, R. | Banjoko, O. | Ndulue, C. | +6

53

Synergistic anti-tumor effects of lenalidomide and gefitinib by upregulating ADRB2 and inactivating the mTOR/PI3K/AKT signaling pathway in lung adenocarcinoma

enthalten in: Cellular and molecular biology (Noisy-le-Grand, France) | 2024

von Zhou, S. | Deng, M. | Bian, X. | +3

54

A Tailored 7- to 10-Day Lenalidomide Desensitization Protocol

enthalten in: Journal of investigational allergology & clinical immunology | 2024

von Pose, K. | Narváez-Fernández, E. | López de la Guía, A. | +5

55

Lenalidomide in the treatment of anti-myelin-associated glycoprotein neuropathy : A phase 1 study to identify the maximum tolerated dose

enthalten in: European journal of neurology | 2024

von Stino, A. | Bumma, N. | Smith, R. | +13

56

enthalten in: Dermatologie (Heidelberg, Germany) | 2024

von Sunderkötter, C. | Bruns, T. | Pfeiffer, C.

57

Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma

enthalten in: Blood | 2024

von D'Agostino, M. | Bertuglia, G. | Rota-Scalabrini, D. | +22

CommentIn: Blood. 2024 Feb 15;143(7):564-566. - PMID 38358852

58

Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma : a cohort of a multicentre, single-arm, phase 1b/2 study

enthalten in: The Lancet. Haematology | 2024

von Abrisqueta, P. | González-Barca, E. | Panizo, C. | +13

59

Belantamab mafodotin, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma : Analysis of belantamab mafodotin-associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1/2 study

enthalten in: American journal of hematology | 2024

von Gavriatopoulou, M. | Ntanasis-Stathopoulos, I. | Malandrakis, P. | +11

60

Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysis

enthalten in: Clinical lymphoma, myeloma & leukemia | 2024

von Chavez, J. | Grajales, A. | Sandoval-Sus, J. | +14